[1]刘延梅,马少君,张月浪,等.人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析[J].现代检验医学杂志,2016,31(05):91-93，96.[doi:10.3969/j.issn.1671-7414.2016.05.024]
　LIU Yan-mei,MA Shao-jun,ZHANG Yue-lang,et al.Expression of Human Epidermal Growth Factor Receptor 2 and Correlation with Clinical Pathological Features in Breast Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):91-93，96.[doi:10.3969/j.issn.1671-7414.2016.05.024]
点击复制

人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第31卷
期数:
2016年05期
页码:
91-93，96
栏目:
论著
出版日期:
2016-10-21

文章信息/Info

Title:
Expression of Human Epidermal Growth Factor Receptor 2 and Correlation with Clinical Pathological Features in Breast Cancer
文章编号:
1671-7414(2016)05-091-04
作者:
刘延梅; 马少君; 张月浪; 康晓丽; 梁晓燕; 周理乾; 李文生
陕西省人民医院西院二病区,西安 710068
Author(s):
LIU Yan-mei; MA Shao-jun; ZHANG Yue-lang;  KANG Xiao-li; LIANG Xiao-yan; ZHOU Li-qian; LI Wen-sheng
the Second Department of Shaanxi Provincial People's Hospital,Xi'an 710068,China
关键词:
乳腺癌;  表皮生长因子受体2;  临床病理特征
分类号:
R373.9; R730.43
DOI:
10.3969/j.issn.1671-7414.2016.05.024
文献标志码:
A
摘要:
目的 评估人类表皮生长因子受体2(HER2)预测价值,并分析其与常见的组织病理学参数的相关性。方法 收集陕西省人民医院2011年～2014年之间160例接受手术治疗的乳腺癌患者组织标本,通过免疫组织化学方法(IHC)和荧光原位杂交(FISH)检测 HER2水平,通过χ2检验用来评估HER2基因扩增状况及不同临床病理特性的相关性,临床参数包括:肿瘤大小、组织学分级、雌激素受体(ER)和孕激素受体(PR)表达,年龄、绝经情况和Ki-67指数。结果 HER-2表达与组织学分级、淋巴结转移、ER水平、PR,Ki-67指数差异存在统计学意义(均P<0.05)。相对于HER-2+组患者,HER-2-病变多表现为雌激素ER阴性、孕激素阴性、ER阴性、淋巴结阴性、ki-67≥20%。结论 HER-2表达与多种临床病理因素存在相关性。
Abstract:
Objective To evaluate of value of HER2 as a prognostic marker,and to analysis associations with common histopathological parameters in BC cases.Methods In this study,formalin-fixed,paraffin-embedded samples of tumors from 160 breast cancer patients who underwent curative surgery proce-dures between 2011 and 2014 were tested by immunohistochemistry(IHC)as aprimary estimate of HER2 status,followed by fluorescencein situ hybridization(FISH).Concordance rate between IHC and FISH was evaluated.The χ2 test was used to evaluate the correlation between HER2 gene amplification status and different clinical pathological features including:(estrogen receptor)ER and(progesterone receptor)PR expression,age,menopausal status and tumor size.Results There was a significant inverse association between expression of hormone receptors(ER and PR)and HER2 amplification(all P<0.05)among the patients studied.However,no relationshipwas observed between HER2 amplification and age,menopausal status and tumor size(P>0.05).HER2-negative lesions were of higher grade and more likely tobe ER-negative,PR-negative,p53-positive,lymph node metastasis,and alsoKi-67≥20% as compared to the HER2-positive group and HER2 overe xpression wasassociated with the levels of ER and PR.Conclusion There is correlation of many clinical factors with HER2 expression.

参考文献/References:

[1] 唐 平,魏 兵,杨雯娟,等.乳腺癌预后/预测因子[J].中华病理学杂志,2011,40(2):73-76. Tang P,Wei B,Yang WJ,et al.Prgnostic factors of breast cancer[J].Chinese Journal of Pathology,2011,40(2):73-76.
[2] Ravdin PM,Siminoff LA,Davis GJ,et al.Computer program to assist inmaking decisions about adjuvant therapy for women with early breast cancer[J].JClin Oneol,200l,19(4):980-991.
[3] Goldhirsch A,Ingle JN,Gelber RD,et al.Thresholds for therapies:highlights of the St Gallen International Expert Consensus on the primary therapy ofearly breast cancer 2009[J].Ann Oncol,2009,20(8):1319-1329.
[4] Carey LA.Through a glass darkly:advances in understanding breast cancer biology,2000～2010[J].Clin Breast Cancer,2010,10(3):188-195.
[5] Jatoi I,Anderson WF,Rosenberg PS.Qualitative age-interactions in breast cancer:a tale of two diseases?[J].Am J Clin Oncol,2008,31(5):504-506.
[6] Figueroa-Magalhaes MC,Jelovac D,Connolly RM,et al.Treatment of HER2-positive breast cancer[J].Current Treatment Options in Oncology,2014,23(2):128-136.
[7] Nishimura R,Osako T,Okumura Y,et al.Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer[J].Exp Ther Med,2010,1(5),747-754.
[8] Patnayak R,Jena A,Rukmangadha N,et al.Hormone receptor status(estrogen receptor,progesterone receptor),human epidermal growth factor-2 and p53 inSouth Indian breast cancer patients:A tertiary care center experience[J].Indian J Med Paediatr Onco,2015,36(2),117-122.
[9] Wolff AC,Hammond ME,Schwartz JN,el al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].Arch Pathol Lab Med,2007,1(1):1843.
[10] Hammond ME,Hayes DF,Dowsett M.et al.American society of Clinical Onology/College of American Pathologists guideline recommendations forimmunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].Arch Pathol Lab Med,2010,134(6):907-922.
[11] 《乳腺癌HER2检测指南(2009版)》编写组.乳腺癌HER2检测指南(2009版)[J].中华病理学杂志,2009,38(12):836-840.

相似文献/References:

[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
　DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2 和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
　ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2 and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
[3]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
　QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(05):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[4]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
　CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(05):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[5]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
　TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell s[J].Journal of Modern Laboratory Medicine,2017,32(05):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[6]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A >T(rs290987)Single Nucleotide Polymorphisms with Susceptibility to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(05):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
　GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[8]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
　LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[9]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
　WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
[10]王承霞,朱玉蓉.乳腺癌患者血清中 tRF-32-Q99P9P9NH57SJ的表达及临床意义[J].现代检验医学杂志,2019,34(06):16.[doi:10.3969 ／ j.issn.1671-7414.2019.06.004]
　WANG Cheng-xia,ZHU Yu-rong.Expression and Clinical Significance of tRF-32-Q99P9P9NH57SJ in Serum of Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):16.[doi:10.3969 ／ j.issn.1671-7414.2019.06.004]

备注/Memo

备注/Memo:
基金项目:陕西社发科技攻关项目(编号:2016SF-168),陕西科学技术研究发展计划项目(编号:2013K-12-03-19)。
作者简介:刘延梅(1976-),女,副主任医师,从事呼吸、老年病治疗工作。
通讯作者:马少君(1975-),男,副主任医师,从事乳腺疾病、骨关节及消化道疾病影像诊断。
更新日期/Last Update: 2016-10-30